{"id":"chlorproguanil-dapsone-artesunate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:59:03.159336","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Chlorproguanil inhibits dihydrofolate reductase, an enzyme essential for the malaria parasite's nucleic acid synthesis. Dapsone has antifolate properties, while artesunate is a potent antimalarial compound that targets the parasite's hemoglobin degradation pathway.","oneSentence":"Chlorproguanil-dapsone-artesunate is a combination antimalarial medication that works by targeting the malaria parasite's metabolic pathways and disrupting its ability to synthesize nucleic acids.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:44.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of uncomplicated Plasmodium falciparum malaria"},{"name":"Prevention of malaria in areas with chloroquine-resistant strains"}]},"_fixedFields":["pubmed(13)"],"trialDetails":[{"nctId":"NCT00146731","phase":"PHASE3","title":"A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2004-01","conditions":"Malaria","enrollment":310},{"nctId":"NCT00519467","phase":"PHASE2","title":"Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Malaria","enrollment":120},{"nctId":"NCT00371735","phase":"PHASE3","title":"Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Malaria, Falciparum","enrollment":900},{"nctId":"NCT00344006","phase":"PHASE3","title":"Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Malaria, Falciparum","enrollment":1395},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT00111163","phase":"NA","title":"Intermittent Preventive Treatment With Antimalarials in Kenyan Infants","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-03","conditions":"Malaria, Anemia","enrollment":1516},{"nctId":"NCT00164359","phase":"PHASE4","title":"Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":"Malaria, Falciparum","enrollment":212},{"nctId":"NCT00164710","phase":"PHASE4","title":"Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-04","conditions":"Malaria, Falciparum","enrollment":365},{"nctId":"NCT00461578","phase":"NA","title":"Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2005-04","conditions":"Malaria","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"chlorproguanil-dapsone-artesunate","genericName":"chlorproguanil-dapsone-artesunate","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chlorproguanil-dapsone-artesunate is a combination antimalarial medication that works by targeting the malaria parasite's metabolic pathways and disrupting its ability to synthesize nucleic acids. Used for Treatment of uncomplicated Plasmodium falciparum malaria, Prevention of malaria in areas with chloroquine-resistant strains.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}